SCHEMBL20599878

SCHEMBL20599878

O=C(O)C(=CNc1ccncc1-c1cccc(Cl)c1Cl)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ JAK2 O60674 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ TYK2 P29597 2/20 0.36
▸ LIMK1 P53667 2/20 0.34
▸ DHODH Q02127 2/20 0.33
▸ MCL1 Q07820 1/20 0.33
▸ ERCC5 P28715 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TLR7 Q9NYK1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20599779 0.90 MEN1 (0.39) MEN1KMT2AKDM4EGAAJAK2
SCHEMBL20600333 0.85 ERCC5 (0.35) MEN1KMT2AKDM4EMAPTDHODH
SCHEMBL20621792 0.83 CYP3A4 (0.50) MEN1KMT2AKDM4EGAAMAPT
SCHEMBL29965238 0.83 CYP3A4 (0.50) MEN1KMT2AKDM4EGAAMAPT
SCHEMBL20600156 0.78 RXFP1 (0.41) MEN1KMT2AKDM4EGAAMAPT
SCHEMBL20621881 0.74 CYP3A4 (0.50) MEN1KMT2AKDM4EGAAMAPT
SCHEMBL20600158 0.71 CCNC (0.40) KMT2AMAPTSMN1; SMN2
SCHEMBL20599776 0.69 GSK3B (0.39) MEN1KMT2AMAPTLMNAROCK2
SCHEMBL20622111 0.68 CYP3A4 (0.52) MEN1KMT2AKDM4EGAAMAPT
SCHEMBL28371995 0.66 MEN1 (0.34) MEN1KMT2AKDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615527-B1 NEW AZAQUINOLINE DERIVATIVES ELANCO ANIMAL HEALTH GMBH (DE) 2024-03-06 — — EP disclosed
US-11485733-B2 Azaquinoline derivatives BAYER ANIMAL HEALTH GMBH (DE) 2022-11-01 — — US disclosed
US-20200131175-A1 NEW AZAQUINOLINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-04-30 — — US disclosed
EP-3615527-A1 NEW AZAQUINOLINE DERIVATIVES Bayer Animal Health GmbH (DE) 2020-03-04 — — EP disclosed
WO-2019002132-A1 NEW AZAQUINOLINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131175-A1 NEW AZAQUINOLINE DERIVATIVES RECQL, H1-5, CHRM1 MEN1 431/4885KMT2A 253/4885KDM4E 1513/4885
US-11485733-B2 Azaquinoline derivatives RECQL, H1-5, H1-3 MEN1 175/4885KMT2A 309/4885KDM4E 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback